ADRI Honour Wall
Late last year ADSS made a donation to the Asbestos Disease Research Institute (ADRI) of $100 000. ADRI has recently recognised the donation by ADSS to ADRI and more importantly to research, not only in their Annual Report but also on their honour wall.
ADRI advises that “this extremely generous donation by the ADSS will enable the ADRI to continue our research, and in particular the MesomiR clinical trial. The “MesomiR1” trial was the world’s first trial to focus on the value of microRNA-based therapy in malignant pleural mesothelioma and non-small cell lung cancer for which essentially no curative treatment options exist.
The concept of the new medication, TargomiRs, resembles the Trojan horse story, where the tumour cells absorb the microRNA (mimics) delivered by minicells thereby slowing/stopping tumour growth. Whilst the results of the MesomiR1 trial were exciting it was a very early observation that requires confirmation in the next phase of the clinical testing. The next stage will focus on efficacy and the very generous donation by the ADSS will contribute to the transition from phase I to ii. The obvious goal of our clinical studies is to eventually add a new form of treatment to the limited therapeutic arsenals for malignant mesothelioma and non-small cell lung cancer; two cancer diagnoses associated with asbestos exposure.”[i]
[i] ADRI, Annual Report 2015